Coronary Calcium: A Comprehensive Understanding of Its Biology, Use in Screening, and Interventional Management provides a comprehensive update on the current understanding of the significance of coronary artery calcification, showing the connection to the development of advanced atherosclerosis that will lead to better risk evaluations. Coverage includes information on the basic science behind the development of coronary calcium in atherosclerotic lesions, the pathology of calcified coronary lesions in humans, its differential development by race, and its relationship to plaque progression. Computed tomography is also covered to show the significance of coronary calcium for risk prediction and the potential role of various pharmacologic interventions.
Each chapter contains summaries with salient and important points, making this book perfect for researchers and physicians interested in the field of vascular calcification.
- Provides an easy-to-read update on the current understanding of coronary calcium from a pathologic perspective
- Offers cutting-edge knowledge on the future of coronary calcium screening and authoritative opinions from experts
- Delivers relevant information for the evaluation of patients who may have coronary artery disease using coronary calcium as evaluated by CT in risk stratification and treatment
Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.
1. Types and Pathology of Vascular Calcification 2. Calcification and Atherosclerosis Progression 3. Basic Molecular Mechanisms of Vascular Calcification 4. CT and Calcification: Understanding its Role in Risk Prediction 5. Intravascular Imaging and Coronary Calcification 6. Influence of Race and Other Risk Factors such as Diabetes and Renal Failure on Coronary Calcification 7. Vascular Calcification in Response to Pharmacologic Intervention 8. Clinical Perspective 9. Imaging of Vascular Calcification: Where Are We Headed?
In January 2016, Dr. Finn joined CVPath as its Medical Director and Chief of Research, and head of the Institute's basic and translational research laboratory. At that time, he was also appointed Associate Professor of Medicine at the University of Maryland, where he serves (part-time) as a cardiologist and interventional cardiologist.
He has published over 100 peer-reviewed research articles, editorials, and reviews. He is an editorial board member of Coronary Artery Disease and of Arteriosclerosis, Thrombosis, and Vascular Biology.
Dr. Finn came to CVPath from Emory University in Atlanta where, from 2007 through 2015, he was Assistant Professor of Medicine and directed a basic and translational research laboratory with work funded by grants from the National Institutes of Health and the American Heart Association. His research interests are in the area of vascular biology, particularly human vascular disease. He has focused in particular on 1) the molecular mechanisms by which mTOR inhibitors delay endothelial recovery and function after vascular injury; 2) the role of alternative macrophage phenotypes in human atherosclerosis; and 3) mechanisms by which the macrophage scavenger receptor CD163 controls tissue regeneration after vascular injury.
He obtained his MD from Vanderbilt University in 2000. During medical school, he received a Howard Hughes Medical Student Research Fellowship and studied vascular gene therapy under David Dichek at the University of California at San Francisco. Dr. Finn did his internal medicine, cardiology and interventional cardiology training at the Massachusetts General Hospital in Boston, including two years of vascular biology research with Drs. Herman Gold and Rakesh Jain.